Amgen and AstraZeneca Report Positive Phase 3 EoE Data
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
Waltham, Massachusetts, July 28, 2026 Dyne Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has cleared...
Ramat-Gan, Israel, July 28, 2026 Galmed Pharmaceuticals Ltd. has announced a significant advancement in the development of Aramchol orally...
